Imatinib in melanoma:: A selective treatment option based on KIT mutation status?

被引：24

作者：

Becker, Juergen C.

Broecker, Eva B.

Schadendorf, Dirk

Ugurel, Selma

机构：

[1] Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany

[2] German Canc Res Ctr, Skin Canc Unit, D-6900 Heidelberg, Germany

[3] Univ Mannheim, Med Ctr, Dept Dermatol, Mannheim, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 07期

关键词：

D O I：

10.1200/JCO.2006.08.9664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E9 / E9

页数：1

共 5 条

[1] Distinct sets of genetic alterations in melanoma [J].

Curtin, JA ;

Fridlyand, J ;

Kageshita, T ;

Patel, HN ;

Busam, KJ ;

Kutzner, H ;

Cho, KH ;

Aiba, S ;

Bröcker, EB ;

LeBoit, PE ;

Pinkel, D ;

Bastian, BC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147

[2] Somatic activation of KIT in distinct subtypes of melanoma [J].

Curtin, John A. ;

Busam, Klaus ;

Pinkel, Daniel ;

Bastian, Boris C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4340-4346

[3]

Frost MJ, 2002, MOL CANCER THER, V1, P1115

[4] Lack of clinical efficacy of imatinib in metastatic melanoma [J].

Ugurel, S ;

Hildenbrand, R ;

Zimpfer, A ;

La Rosée, P ;

Paschka, P ;

Sucker, A ;

Keikavoussi, P ;

Becker, JC ;

Rittgen, W ;

Hochhaus, A ;

Schadendorf, D .

BRITISH JOURNAL OF CANCER, 2005, 92 (08) :1398-1405

[5] Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma - Significant toxicity with no clinical efficacy [J].

Wyman, K ;

Atkins, MB ;

Prieto, V ;

Eton, O ;

McDermott, DF ;

Hubbard, F ;

Byrnes, C ;

Sanders, K ;

Sosman, JA .

CANCER, 2006, 106 (09) :2005-2011

← 1 →